Ptc Therapeutics (PTCT) Income from Continuing Operations (2012 - 2026)
Ptc Therapeutics' (PTCT) quarterly Income from Continuing Operations came in at 2809000.0 in Q1 2026, down 100.32% year-on-year from 866562000.0 in Q1 2025, and up 97.76% quarter-over-quarter from 125387000.0 in Q4 2025.
Ptc Therapeutics (PTCT) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 2809000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 100.32% year-over-year to 2809000.0 in Q1 2026; TTM through Mar 2026 was 177149000.0, a 115.18% decrease from a year earlier, with the FY2025 full-year figure at 692222000.0, up 231.38% from the prior year.
- Income from Continuing Operations improved to 2809000.0 in Q1 2026 per PTCT's latest filing, from 125387000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 866562000.0 in Q1 2025 and bottomed at 286706000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 109315000.0 (2022), against an average of 26739117.65.
- Biggest YoY gain for Income from Continuing Operations was 1046.28% in 2025; the steepest drop was 124.77% in 2025.
- Year by year, Income from Continuing Operations stood at 207222000.0 in 2022, then tumbled by 38.36% to 286706000.0 in 2023, then soared by 276.59% to 506299000.0 in 2024, then plunged by 124.77% to 125387000.0 in 2025, then surged by 97.76% to 2809000.0 in 2026.
- Per Business Quant, the three latest PTCT Income from Continuing Operations figures stand at 2809000.0 (Q1 2026), 125387000.0 (Q4 2025), and 15896000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Ptc Therapeutics | 6.34 Bn | 4.45 Bn | 244.52 Mn | -2.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.81 Mn |
| Dec 31, 2025 | -125.39 Mn |
| Sep 30, 2025 | 15.90 Mn |
| Jun 30, 2025 | -64.85 Mn |
| Mar 31, 2025 | 866.56 Mn |
| Dec 31, 2024 | 506.30 Mn |
| Sep 30, 2024 | -106.65 Mn |
| Jun 30, 2024 | -99.18 Mn |
| Mar 31, 2024 | -91.58 Mn |
| Dec 31, 2023 | -286.71 Mn |
| Sep 30, 2023 | -132.97 Mn |
| Jun 30, 2023 | -198.88 Mn |
| Mar 31, 2023 | -138.96 Mn |
| Dec 31, 2022 | -207.22 Mn |
| Sep 30, 2022 | -109.32 Mn |
| Jun 30, 2022 | -152.09 Mn |
| Mar 31, 2022 | -126.73 Mn |
| Dec 31, 2021 | -139.04 Mn |
| Sep 30, 2021 | -133.62 Mn |
| Jun 30, 2021 | -118.37 Mn |